ldos-20230929false2023Q3000133692012/29http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrent21200013369202022-12-312023-09-2900013369202023-10-24xbrli:shares00013369202023-09-29iso4217:USD00013369202022-12-30iso4217:USDxbrli:shares00013369202023-07-012023-09-2900013369202022-07-022022-09-3000013369202022-01-012022-09-300001336920us-gaap:CommonStockMember2022-12-300001336920us-gaap:AdditionalPaidInCapitalMember2022-12-300001336920us-gaap:RetainedEarningsMember2022-12-300001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-300001336920us-gaap:ParentMember2022-12-300001336920us-gaap:NoncontrollingInterestMember2022-12-300001336920us-gaap:RetainedEarningsMember2022-12-312023-03-310001336920us-gaap:ParentMember2022-12-312023-03-310001336920us-gaap:NoncontrollingInterestMember2022-12-312023-03-3100013369202022-12-312023-03-310001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-312023-03-310001336920us-gaap:AdditionalPaidInCapitalMember2022-12-312023-03-310001336920us-gaap:CommonStockMember2023-03-310001336920us-gaap:AdditionalPaidInCapitalMember2023-03-310001336920us-gaap:RetainedEarningsMember2023-03-310001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001336920us-gaap:ParentMember2023-03-310001336920us-gaap:NoncontrollingInterestMember2023-03-3100013369202023-03-310001336920us-gaap:RetainedEarningsMember2023-04-012023-06-300001336920us-gaap:ParentMember2023-04-012023-06-300001336920us-gaap:NoncontrollingInterestMember2023-04-012023-06-3000013369202023-04-012023-06-300001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001336920us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001336920us-gaap:CommonStockMember2023-06-300001336920us-gaap:AdditionalPaidInCapitalMember2023-06-300001336920us-gaap:RetainedEarningsMember2023-06-300001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001336920us-gaap:ParentMember2023-06-300001336920us-gaap:NoncontrollingInterestMember2023-06-3000013369202023-06-300001336920us-gaap:RetainedEarningsMember2023-07-012023-09-290001336920us-gaap:ParentMember2023-07-012023-09-290001336920us-gaap:NoncontrollingInterestMember2023-07-012023-09-290001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-290001336920us-gaap:CommonStockMember2023-07-012023-09-290001336920us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-290001336920us-gaap:CommonStockMember2023-09-290001336920us-gaap:AdditionalPaidInCapitalMember2023-09-290001336920us-gaap:RetainedEarningsMember2023-09-290001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-290001336920us-gaap:ParentMember2023-09-290001336920us-gaap:NoncontrollingInterestMember2023-09-290001336920us-gaap:CommonStockMember2021-12-310001336920us-gaap:AdditionalPaidInCapitalMember2021-12-310001336920us-gaap:RetainedEarningsMember2021-12-310001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001336920us-gaap:ParentMember2021-12-310001336920us-gaap:NoncontrollingInterestMember2021-12-3100013369202021-12-310001336920us-gaap:RetainedEarningsMember2022-01-012022-04-010001336920us-gaap:ParentMember2022-01-012022-04-010001336920us-gaap:NoncontrollingInterestMember2022-01-012022-04-0100013369202022-01-012022-04-010001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-04-010001336920us-gaap:CommonStockMember2022-01-012022-04-010001336920us-gaap:AdditionalPaidInCapitalMember2022-01-012022-04-010001336920us-gaap:CommonStockMember2022-04-010001336920us-gaap:AdditionalPaidInCapitalMember2022-04-010001336920us-gaap:RetainedEarningsMember2022-04-010001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-010001336920us-gaap:ParentMember2022-04-010001336920us-gaap:NoncontrollingInterestMember2022-04-0100013369202022-04-010001336920us-gaap:RetainedEarningsMember2022-04-022022-07-010001336920us-gaap:ParentMember2022-04-022022-07-010001336920us-gaap:NoncontrollingInterestMember2022-04-022022-07-0100013369202022-04-022022-07-010001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-022022-07-010001336920us-gaap:AdditionalPaidInCapitalMember2022-04-022022-07-010001336920us-gaap:CommonStockMember2022-07-010001336920us-gaap:AdditionalPaidInCapitalMember2022-07-010001336920us-gaap:RetainedEarningsMember2022-07-010001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-010001336920us-gaap:ParentMember2022-07-010001336920us-gaap:NoncontrollingInterestMember2022-07-0100013369202022-07-010001336920us-gaap:RetainedEarningsMember2022-07-022022-09-300001336920us-gaap:ParentMember2022-07-022022-09-300001336920us-gaap:NoncontrollingInterestMember2022-07-022022-09-300001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-022022-09-300001336920us-gaap:AdditionalPaidInCapitalMember2022-07-022022-09-300001336920us-gaap:CommonStockMember2022-09-300001336920us-gaap:AdditionalPaidInCapitalMember2022-09-300001336920us-gaap:RetainedEarningsMember2022-09-300001336920us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001336920us-gaap:ParentMember2022-09-300001336920us-gaap:NoncontrollingInterestMember2022-09-3000013369202022-09-300001336920ldos:LeidosIncMember2023-09-29xbrli:pureldos:segment0001336920us-gaap:CashAndCashEquivalentsMember2023-09-290001336920us-gaap:CashAndCashEquivalentsMember2022-12-300001336920ldos:PerformancePeriodOneMember2023-09-302023-09-2900013369202024-09-28ldos:PerformancePeriodTwoMember2023-09-2900013369202023-09-302023-09-2900013369202024-09-282023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberldos:USDoDAndUSIntelligenceCommunityMember2023-07-012023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:HealthSegmentMember2023-07-012023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMember2023-07-012023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberldos:USDoDAndUSIntelligenceCommunityMember2022-12-312023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:HealthSegmentMember2022-12-312023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMember2022-12-312023-09-290001336920ldos:OtherGovernmentAgenciesMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberldos:OtherGovernmentAgenciesMember2023-07-012023-09-290001336920ldos:OtherGovernmentAgenciesMemberldos:HealthSegmentMember2023-07-012023-09-290001336920ldos:OtherGovernmentAgenciesMember2023-07-012023-09-290001336920ldos:OtherGovernmentAgenciesMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberldos:OtherGovernmentAgenciesMember2022-12-312023-09-290001336920ldos:OtherGovernmentAgenciesMemberldos:HealthSegmentMember2022-12-312023-09-290001336920ldos:OtherGovernmentAgenciesMember2022-12-312023-09-290001336920ldos:CommercialAndNonUSCustomersMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CommercialAndNonUSCustomersMemberldos:CivilSegmentMember2023-07-012023-09-290001336920ldos:CommercialAndNonUSCustomersMemberldos:HealthSegmentMember2023-07-012023-09-290001336920ldos:CommercialAndNonUSCustomersMember2023-07-012023-09-290001336920ldos:CommercialAndNonUSCustomersMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CommercialAndNonUSCustomersMemberldos:CivilSegmentMember2022-12-312023-09-290001336920ldos:CommercialAndNonUSCustomersMemberldos:HealthSegmentMember2022-12-312023-09-290001336920ldos:CommercialAndNonUSCustomersMember2022-12-312023-09-290001336920ldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CivilSegmentMember2023-07-012023-09-290001336920ldos:HealthSegmentMember2023-07-012023-09-290001336920ldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CivilSegmentMember2022-12-312023-09-290001336920ldos:HealthSegmentMember2022-12-312023-09-290001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CivilSegmentMemberldos:USDoDAndUSIntelligenceCommunityMember2022-07-022022-09-300001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:HealthSegmentMember2022-07-022022-09-300001336920ldos:USDoDAndUSIntelligenceCommunityMember2022-07-022022-09-300001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CivilSegmentMemberldos:USDoDAndUSIntelligenceCommunityMember2022-01-012022-09-300001336920ldos:USDoDAndUSIntelligenceCommunityMemberldos:HealthSegmentMember2022-01-012022-09-300001336920ldos:USDoDAndUSIntelligenceCommunityMember2022-01-012022-09-300001336920ldos:OtherGovernmentAgenciesMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CivilSegmentMemberldos:OtherGovernmentAgenciesMember2022-07-022022-09-300001336920ldos:OtherGovernmentAgenciesMemberldos:HealthSegmentMember2022-07-022022-09-300001336920ldos:OtherGovernmentAgenciesMember2022-07-022022-09-300001336920ldos:OtherGovernmentAgenciesMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CivilSegmentMemberldos:OtherGovernmentAgenciesMember2022-01-012022-09-300001336920ldos:OtherGovernmentAgenciesMemberldos:HealthSegmentMember2022-01-012022-09-300001336920ldos:OtherGovernmentAgenciesMember2022-01-012022-09-300001336920ldos:CommercialAndNonUSCustomersMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CommercialAndNonUSCustomersMemberldos:CivilSegmentMember2022-07-022022-09-300001336920ldos:CommercialAndNonUSCustomersMemberldos:HealthSegmentMember2022-07-022022-09-300001336920ldos:CommercialAndNonUSCustomersMember2022-07-022022-09-300001336920ldos:CommercialAndNonUSCustomersMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CommercialAndNonUSCustomersMemberldos:CivilSegmentMember2022-01-012022-09-300001336920ldos:CommercialAndNonUSCustomersMemberldos:HealthSegmentMember2022-01-012022-09-300001336920ldos:CommercialAndNonUSCustomersMember2022-01-012022-09-300001336920ldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CivilSegmentMember2022-07-022022-09-300001336920ldos:HealthSegmentMember2022-07-022022-09-300001336920ldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CivilSegmentMember2022-01-012022-09-300001336920ldos:HealthSegmentMember2022-01-012022-09-300001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberldos:CostReimbursementAndFixedPriceIncentiveFeeMember2023-07-012023-09-290001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:HealthSegmentMember2023-07-012023-09-290001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMember2023-07-012023-09-290001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberldos:CostReimbursementAndFixedPriceIncentiveFeeMember2022-12-312023-09-290001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:HealthSegmentMember2022-12-312023-09-290001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMember2022-12-312023-09-290001336920us-gaap:FixedPriceContractMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberus-gaap:FixedPriceContractMember2023-07-012023-09-290001336920us-gaap:FixedPriceContractMemberldos:HealthSegmentMember2023-07-012023-09-290001336920us-gaap:FixedPriceContractMember2023-07-012023-09-290001336920us-gaap:FixedPriceContractMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberus-gaap:FixedPriceContractMember2022-12-312023-09-290001336920us-gaap:FixedPriceContractMemberldos:HealthSegmentMember2022-12-312023-09-290001336920us-gaap:FixedPriceContractMember2022-12-312023-09-290001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2023-07-012023-09-290001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:HealthSegmentMember2023-07-012023-09-290001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2023-07-012023-09-290001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2022-12-312023-09-290001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:HealthSegmentMember2022-12-312023-09-290001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2022-12-312023-09-290001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CivilSegmentMemberldos:CostReimbursementAndFixedPriceIncentiveFeeMember2022-07-022022-09-300001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:HealthSegmentMember2022-07-022022-09-300001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMember2022-07-022022-09-300001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CivilSegmentMemberldos:CostReimbursementAndFixedPriceIncentiveFeeMember2022-01-012022-09-300001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMemberldos:HealthSegmentMember2022-01-012022-09-300001336920ldos:CostReimbursementAndFixedPriceIncentiveFeeMember2022-01-012022-09-300001336920us-gaap:FixedPriceContractMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CivilSegmentMemberus-gaap:FixedPriceContractMember2022-07-022022-09-300001336920us-gaap:FixedPriceContractMemberldos:HealthSegmentMember2022-07-022022-09-300001336920us-gaap:FixedPriceContractMember2022-07-022022-09-300001336920us-gaap:FixedPriceContractMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CivilSegmentMemberus-gaap:FixedPriceContractMember2022-01-012022-09-300001336920us-gaap:FixedPriceContractMemberldos:HealthSegmentMember2022-01-012022-09-300001336920us-gaap:FixedPriceContractMember2022-01-012022-09-300001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920ldos:CivilSegmentMemberldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2022-07-022022-09-300001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:HealthSegmentMember2022-07-022022-09-300001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2022-07-022022-09-300001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920ldos:CivilSegmentMemberldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2022-01-012022-09-300001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMemberldos:HealthSegmentMember2022-01-012022-09-300001336920ldos:TimeAndMaterialsAndFixedPriceLevelOfEffortMember2022-01-012022-09-300001336920country:USldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920country:USldos:CivilSegmentMember2023-07-012023-09-290001336920country:USldos:HealthSegmentMember2023-07-012023-09-290001336920country:US2023-07-012023-09-290001336920country:USldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920country:USldos:CivilSegmentMember2022-12-312023-09-290001336920country:USldos:HealthSegmentMember2022-12-312023-09-290001336920country:US2022-12-312023-09-290001336920us-gaap:NonUsMemberldos:DefenseSolutionsSegmentMember2023-07-012023-09-290001336920us-gaap:NonUsMemberldos:CivilSegmentMember2023-07-012023-09-290001336920us-gaap:NonUsMemberldos:HealthSegmentMember2023-07-012023-09-290001336920us-gaap:NonUsMember2023-07-012023-09-290001336920us-gaap:NonUsMemberldos:DefenseSolutionsSegmentMember2022-12-312023-09-290001336920us-gaap:NonUsMemberldos:CivilSegmentMember2022-12-312023-09-290001336920us-gaap:NonUsMemberldos:HealthSegmentMember2022-12-312023-09-290001336920us-gaap:NonUsMember2022-12-312023-09-290001336920country:USldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920country:USldos:CivilSegmentMember2022-07-022022-09-300001336920country:USldos:HealthSegmentMember2022-07-022022-09-300001336920country:US2022-07-022022-09-300001336920country:USldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920country:USldos:CivilSegmentMember2022-01-012022-09-300001336920country:USldos:HealthSegmentMember2022-01-012022-09-300001336920country:US2022-01-012022-09-300001336920us-gaap:NonUsMemberldos:DefenseSolutionsSegmentMember2022-07-022022-09-300001336920us-gaap:NonUsMemberldos:CivilSegmentMember2022-07-022022-09-300001336920us-gaap:NonUsMemberldos:HealthSegmentMember2022-07-022022-09-300001336920us-gaap:NonUsMember2022-07-022022-09-300001336920us-gaap:NonUsMemberldos:DefenseSolutionsSegmentMember2022-01-012022-09-300001336920us-gaap:NonUsMemberldos:CivilSegmentMember2022-01-012022-09-300001336920us-gaap:NonUsMemberldos:HealthSegmentMember2022-01-012022-09-300001336920us-gaap:NonUsMember2022-01-012022-09-300001336920ldos:CobhamSpecialMissionMember2022-10-302022-10-30iso4217:AUD0001336920ldos:CobhamSpecialMissionMember2022-10-3000013369202022-10-300001336920us-gaap:ContractBasedIntangibleAssetsMemberldos:CobhamSpecialMissionMember2022-12-312023-09-290001336920us-gaap:ContractBasedIntangibleAssetsMemberldos:CobhamSpecialMissionMember2023-09-290001336920us-gaap:ComputerSoftwareIntangibleAssetMemberldos:CobhamSpecialMissionMember2022-12-312023-09-290001336920us-gaap:ComputerSoftwareIntangibleAssetMemberldos:CobhamSpecialMissionMember2023-09-290001336920ldos:CobhamSpecialMissionMember2022-12-312023-09-290001336920ldos:CobhamSpecialMissionMember2023-09-290001336920ldos:CobhamSpecialMissionMember2023-07-012023-09-290001336920ldos:DefenseSolutionsSegmentMember2021-12-310001336920ldos:CivilSegmentMember2021-12-310001336920ldos:HealthSegmentMember2021-12-310001336920ldos:DefenseSolutionsSegmentMember2022-01-012022-12-300001336920ldos:CivilSegmentMember2022-01-012022-12-300001336920ldos:HealthSegmentMember2022-01-012022-12-3000013369202022-01-012022-12-300001336920ldos:DefenseSolutionsSegmentMember2022-12-300001336920ldos:CivilSegmentMember2022-12-300001336920ldos:HealthSegmentMember2022-12-300001336920ldos:DefenseSolutionsSegmentMember2023-09-290001336920ldos:CivilSegmentMember2023-09-290001336920ldos:HealthSegmentMember2023-09-290001336920ldos:CivilSegmentMemberldos:SecurityEnterpriseSolutionsMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberldos:SecurityEnterpriseSolutionsMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberldos:SecurityEnterpriseSolutionsMember2023-09-290001336920us-gaap:ContractBasedIntangibleAssetsMember2023-09-290001336920us-gaap:ContractBasedIntangibleAssetsMember2022-12-300001336920us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-290001336920us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-300001336920us-gaap:CustomerRelationshipsMember2023-09-290001336920us-gaap:CustomerRelationshipsMember2022-12-300001336920us-gaap:TradeNamesMember2023-09-290001336920us-gaap:TradeNamesMember2022-12-300001336920us-gaap:InProcessResearchAndDevelopmentMember2023-09-290001336920us-gaap:InProcessResearchAndDevelopmentMember2022-12-300001336920us-gaap:TradeNamesMember2023-09-290001336920us-gaap:TradeNamesMember2022-12-300001336920us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-290001336920us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-290001336920us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-300001336920us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-300001336920us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-09-290001336920us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-300001336920us-gaap:InterestRateSwapMemberus-gaap:OtherAssetsMemberus-gaap:CashFlowHedgingMember2023-09-290001336920us-gaap:InterestRateSwapMemberus-gaap:OtherAssetsMemberus-gaap:CashFlowHedgingMember2022-12-300001336920us-gaap:UnsecuredDebtMemberus-gaap:DesignatedAsHedgingInstrumentMemberldos:InterestRateSwapMaturityDateAugustTwentyTwentyFiveMember2023-09-290001336920ldos:InterestIncomeExpenseNetMember2023-07-012023-09-290001336920ldos:InterestIncomeExpenseNetMember2022-07-022022-09-300001336920ldos:InterestIncomeExpenseNetMember2022-12-312023-09-290001336920ldos:InterestIncomeExpenseNetMember2022-01-012022-09-300001336920ldos:TermLoanDueMayTwentyThousandTwentyThreeMemberus-gaap:UnsecuredDebtMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueMayTwentyThousandTwentyThreeMember2023-09-290001336920ldos:TermLoanDueMayTwentyThousandTwentyThreeMemberus-gaap:UnsecuredDebtMember2022-12-300001336920us-gaap:UnsecuredDebtMember2023-09-290001336920us-gaap:UnsecuredDebtMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueJanuaryTwentyThousandTwentyFiveMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueJanuaryTwentyThousandTwentyFiveMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueMarchTwentyThousandTwentyEightMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueMarchTwentyThousandTwentyEightMember2022-12-300001336920ldos:NotesWhichMatureOnMayTwoThousandTwentyThreeMemberus-gaap:UnsecuredDebtMember2023-09-290001336920ldos:NotesWhichMatureOnMayTwoThousandTwentyThreeMemberus-gaap:UnsecuredDebtMember2022-12-300001336920ldos:NotesWhichMatureOnMayTwoThousandTwentyFiveMemberus-gaap:UnsecuredDebtMember2023-09-290001336920ldos:NotesWhichMatureOnMayTwoThousandTwentyFiveMemberus-gaap:UnsecuredDebtMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnMayTwoThousandThirtyMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnMayTwoThousandThirtyMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueMarchTwoThousandThirtyThreeMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:TermLoanDueMarchTwoThousandThirtyThreeMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnFebruaryTwoThousandThirtyOneMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnFebruaryTwoThousandThirtyOneMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnJulyTwoThousandThirtyTwoMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnJulyTwoThousandThirtyTwoMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnJulyTwoThousandThirtyThreeMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnJulyTwoThousandThirtyThreeMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnDecemberTwoThousandFortyMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnDecemberTwoThousandFortyMember2022-12-300001336920us-gaap:UnsecuredDebtMemberldos:FinanceLeasesDueOnVariousDatesThroughFiscalTwoThousandThirtyTwoMembersrt:MinimumMember2023-09-290001336920us-gaap:UnsecuredDebtMembersrt:MaximumMemberldos:FinanceLeasesDueOnVariousDatesThroughFiscalTwoThousandThirtyTwoMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:FinanceLeasesDueOnVariousDatesThroughFiscalTwoThousandThirtyTwoMember2023-09-290001336920us-gaap:UnsecuredDebtMemberldos:FinanceLeasesDueOnVariousDatesThroughFiscalTwoThousandThirtyTwoMember2022-12-300001336920ldos:TermLoanMemberus-gaap:UnsecuredDebtMemberldos:TheCreditAgreementMember2023-03-100001336920us-gaap:RevolvingCreditFacilityMemberldos:TheCreditAgreementMemberus-gaap:LineOfCreditMember2023-03-100001336920ldos:TheCreditAgreementMember2023-03-102023-03-10ldos:extension0001336920us-gaap:RevolvingCreditFacilityMemberldos:TheCreditAgreementMemberus-gaap:LineOfCreditMember2023-09-290001336920ldos:TermLoanMemberus-gaap:UnsecuredDebtMemberldos:TheCreditAgreementMember2023-09-290001336920ldos:TermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:UnsecuredDebtMember2023-03-102023-03-100001336920ldos:TheCreditAgreementMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-03-102023-03-100001336920srt:MaximumMemberldos:TheCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-03-102023-03-100001336920ldos:TheCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-03-102023-03-100001336920ldos:TheCreditAgreementMember2023-09-290001336920ldos:TheCreditAgreementMember2022-12-312023-09-29ldos:increase0001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnMarchTwoThousandThirtyThreeMember2023-02-280001336920us-gaap:UnsecuredDebtMemberldos:NotesWhichMatureOnMarchTwoThousandThirtyThreeMember2023-02-282023-02-280001336920ldos:NotesMaturingMayTwoThousandTwentyThreeMemberus-gaap:UnsecuredDebtMember2023-02-280001336920us-gaap:UnsecuredDebtMemberldos:NotesMaturingMayTwoThousandTwentyThreeMember2023-02-280001336920ldos:TermLoanMemberus-gaap:UnsecuredDebtMemberldos:TheCreditAgreementMember2023-02-282023-02-280001336920us-gaap:CommercialPaperMember2023-05-262023-05-260001336920us-gaap:CommercialPaperMember2023-09-290001336920us-gaap:CommercialPaperMember2022-12-312023-09-290001336920us-gaap:FlightEquipmentMember2022-12-30ldos:aircraft0001336920us-gaap:FlightEquipmentMember2023-03-310001336920us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001336920us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001336920us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001336920us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-300001336920us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-300001336920us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-300001336920us-gaap:AccumulatedTranslationAdjustmentMember2022-12-300001336920us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-300001336920us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-300001336920us-gaap:AccumulatedTranslationAdjustmentMember2022-12-312023-09-290001336920us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-312023-09-290001336920us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-312023-09-290001336920us-gaap:AccumulatedTranslationAdjustmentMember2023-09-290001336920us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-290001336920us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-290001336920ldos:EquityAwardsMember2023-07-012023-09-290001336920ldos:EquityAwardsMember2022-12-312023-09-290001336920ldos:DefenseSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-290001336920ldos:DefenseSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2022-07-022022-09-300001336920ldos:DefenseSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2022-12-312023-09-290001336920ldos:DefenseSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001336920ldos:CivilSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-290001336920ldos:CivilSegmentMemberus-gaap:OperatingSegmentsMember2022-07-022022-09-300001336920ldos:CivilSegmentMemberus-gaap:OperatingSegmentsMember2022-12-312023-09-290001336920ldos:CivilSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001336920ldos:HealthSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-290001336920ldos:HealthSegmentMemberus-gaap:OperatingSegmentsMember2022-07-022022-09-300001336920ldos:HealthSegmentMemberus-gaap:OperatingSegmentsMember2022-12-312023-09-290001336920ldos:HealthSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001336920us-gaap:CorporateNonSegmentMember2023-07-012023-09-290001336920us-gaap:CorporateNonSegmentMember2022-07-022022-09-300001336920us-gaap:CorporateNonSegmentMember2022-12-312023-09-290001336920us-gaap:CorporateNonSegmentMember2022-01-012022-09-300001336920ldos:VirnetXIncMember2018-04-102018-04-100001336920ldos:VirnetXIncMember2018-08-302018-08-300001336920ldos:VirnetXIncMember2019-11-222019-11-22ldos:patent0001336920ldos:VirnetXIncMember2020-10-302020-10-300001336920ldos:VirnetXIncMember2021-01-012021-01-310001336920ldos:LeidosMember2021-01-3100013369202022-08-31ldos:government_procurement0001336920us-gaap:StandbyLettersOfCreditMember2023-09-290001336920us-gaap:PerformanceGuaranteeMember2023-09-290001336920ldos:StandbyLettersofCreditandSuretyBondsMember2023-09-290001336920ldos:JamesRMoosMember2023-07-012023-09-290001336920ldos:JamesRMoosMember2023-09-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
| | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 29, 2023
or | | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 001-33072 | | | | | | | | |
| Leidos Holdings, Inc. | |
(Exact name of registrant as specified in its charter) | |
| | | | | | | | | | | | | | | | | |
Delaware | | 20-3562868 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| | | | | |
1750 Presidents Street, | Reston, | Virginia | | 20190 |
(Address of principal executive offices) | | (Zip Code) |
| | | | | |
(571) 526-6000
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: | | | | | | | | | | | | | | |
Title of each class | | Trading symbol(s) | | Name of each exchange on which registered |
Common stock, par value $.0001 per share | | LDOS | | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Large accelerated filer | ☒ | | | | | Accelerated filer | ☐ | |
| Non-accelerated filer | ☐ | | | Smaller reporting company | ☐ | |
| | | | | | | Emerging growth company | ☐ | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares issued and outstanding of each of the issuer’s classes of common stock as of October 24, 2023, was 137,506,428 shares of common stock ($.0001 par value per share).
LEIDOS HOLDINGS, INC.
FORM 10-Q
TABLE OF CONTENTS | | | | | | | | |
Part I | | Page |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 3. | | |
Item 4. | | |
Part II | | |
Item 1. | | |
Item 1A. | | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
Item 5. | | |
Item 6. | | |
| | |
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS | | | | | | | | | | | | | | |
| | September 29, 2023 | | December 30, 2022 |
| | (unaudited; in millions, except share and per share data) |
Assets: | | | | |
Cash and cash equivalents | | $ | 750 | | | $ | 516 | |
Receivables, net | | 2,452 | | | 2,350 | |
Inventory, net | | 295 | | | 287 | |
Other current assets | | 494 | | | 490 | |
Total current assets | | 3,991 | | | 3,643 | |
Property, plant and equipment, net | | 935 | | | 847 | |
Intangible assets, net | | 713 | | | 952 | |
Goodwill | | 6,079 | | | 6,696 | |
Operating lease right-of-use assets, net | | 512 | | | 545 | |
Other long-term assets | | 527 | | | 388 | |
Total assets | | $ | 12,757 | | | $ | 13,071 | |
| | | | |
Liabilities: | | | | |
Accounts payable and accrued liabilities | | $ | 2,221 | | | $ | 2,254 | |
Accrued payroll and employee benefits | | 801 | | | 701 | |
Short-term debt and current portion of long-term debt | | 18 | | | 992 | |
Total current liabilities | | 3,040 | | | 3,947 | |
Long-term debt, net of current portion | | 4,667 | | | 3,928 | |
Operating lease liabilities | | 527 | | | 570 | |
Deferred tax liabilities | | 6 | | | 40 | |
Other long-term liabilities | | 314 | | | 233 | |
Total liabilities | | 8,554 | | | 8,718 | |
| | | | |
Commitments and contingencies (Note 11) | | | | |
| | | | |
Stockholders’ equity: | | | | |
Common stock, $0.0001 par value, 500,000,000 shares authorized,137,506,136 and 136,926,990 shares issued and outstanding at September 29, 2023, and December 30, 2022, respectively | | — | | | — | |
Additional paid-in capital | | 2,055 | | | 2,005 | |
Retained earnings | | 2,186 | | | 2,367 | |
Accumulated other comprehensive loss | | (95) | | | (73) | |
Total Leidos stockholders’ equity | | 4,146 | | | 4,299 | |
Non-controlling interest | | 57 | | | 54 | |
Total stockholders' equity | | 4,203 | | | 4,353 | |
Total liabilities and stockholders' equity | | $ | 12,757 | | | $ | 13,071 | |
See accompanying notes to condensed consolidated financial statements.
1
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 29, 2023 | | September 30, 2022 | | September 29, 2023 | | September 30, 2022 |
| | (unaudited; in millions, except per share data) |
Revenues | | $ | 3,921 | | | $ | 3,608 | | | $ | 11,458 | | | $ | 10,699 | |
Cost of revenues | | 3,334 | | | 3,095 | | | 9,809 | | | 9,136 | |
Selling, general and administrative expenses | | 239 | | | 232 | | | 709 | | | 730 |
Acquisition, integration and restructuring costs | | 5 | | | 4 | | | 14 | | | 12 | |
Goodwill impairment charges | | 599 | | | — | | | 599 | | | — | |
Asset impairment charges | | 88 | | | — | | | 88 | | | 3 | |
Equity earnings of non-consolidated subsidiaries | | (8) | | | (4) | | | (21) | | | (5) | |
Operating (loss) income | | (336) | | | 281 | | | 260 | | | 823 | |
Non-operating income (expense): | | | | | | | | |
Interest expense, net | | (53) | | | (50) | | | (163) | | | (148) | |
Other income (expense), net | | 1 | | | (10) | | | (4) | | | (7) | |
(Loss) income before income taxes | | (388) | | | 221 | | | 93 | | | 668 | |
Income tax expense | | (8) | | | (57) | | | (115) | | | (155) | |
Net (loss) income | | $ | (396) | | | $ | 164 | | | $ | (22) | | | $ | 513 | |
Less: net income attributable to non-controlling interest | | 3 | | | 2 | | | 8 | | | 5 | |
Net (loss) income attributable to Leidos common stockholders | | $ | (399) | | | $ | 162 | | | $ | (30) | | | $ | 508 | |
| | | | | | | | |
Earnings per share: | | | | | | | | |
Basic | | $ | (2.91) | | | $ | 1.18 | | | $ | (0.22) | | | $ | 3.71 | |
Diluted | | (2.91) | | | 1.17 | | | (0.22) | | | 3.68 | |
See accompanying notes to condensed consolidated financial statements.
2
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 29, 2023 | | September 30, 2022 | | September 29, 2023 | | September 30, 2022 |
| | (unaudited; in millions) |
Net (loss) income | | $ | (396) | | | $ | 164 | | | $ | (22) | | | $ | 513 | |
Foreign currency translation adjustments | | (31) | | | (75) | | | (19) | | | (158) | |
Unrecognized gain (loss) on derivative instruments | | — | | | 18 | | | (1) | | | 54 | |
Pension adjustments | | (1) | | | 1 | | | (2) | | | (19) | |
Total other comprehensive (loss) income, net of taxes | | (32) | | | (56) | | | (22) | | | (123) | |
Comprehensive (loss) income | | (428) | | | 108 | | | (44) | | | 390 | |
Less: net income attributable to non-controlling interest | | 3 | | | 2 | | | 8 | | | 5 | |
Comprehensive (loss) income attributable to Leidos common stockholders | | $ | (431) | | | $ | 106 | | | $ | (52) | | | $ | 385 | |
See accompanying notes to condensed consolidated financial statements.
3
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Shares of common stock | | Additional paid-in capital | | Retained earnings | | Accumulated other comprehensive income (loss) | | Leidos stockholders' equity | | Non-controlling interest | | Total stockholders' equity |
| | (unaudited; in millions, except per share data) |
Balance at December 30, 2022 | | 137 | | | $ | 2,005 | | | $ | 2,367 | | | $ | (73) | | | $ | 4,299 | | | $ | 54 | | | $ | 4,353 | |
Net income | | — | | | — | | | 162 | | | — | | | 162 | | | 2 | | | 164 | |
Other comprehensive income, net of taxes | | — | | | — | | | — | | | 9 | | | 9 | | | — | | | 9 | |
Issuances of stock | | — | | | 14 | | | — | | | — | | | 14 | | | — | | | 14 | |
Repurchases of stock and other | | — | | | (43) | | | — | | | — | | | (43) | | | — | | | (43) | |
Dividends of $0.36 per share | | — | | | — | | | (50) | | | — | | | (50) | | | — | | | (50) | |
Stock-based compensation | | — | | | 18 | | | — | | | — | | | 18 | | | — | | | 18 | |
Net capital distributions to non-controlling interest | | — | | | — | | | — | | | — | | | — | | | (1) | | | (1) | |
Balance at March 31, 2023 | | 137 | | | $ | 1,994 | | | $ | 2,479 | | | $ | (64) | | | $ | 4,409 | | | $ | 55 | | | $ | 4,464 | |
Net income | | — | | | — | | | 207 | | | — | | | 207 | | | 3 | | | 210 | |
Other comprehensive income, net of taxes | | — | | | — | | | — | | | 1 | | | 1 | | | — | | | 1 | |
Issuances of stock | | — | | | 14 | | | — | | | — | | | 14 | | | — | | | 14 | |
| | | | | | | | | | | | | | |
Dividends of $0.36 per share | | — | | | — | | | (50) | | | — | | | (50) | | | — | | | (50) | |
Stock-based compensation | | — | | | 19 | | | — | | | — | | | 19 | | | — | | | 19 | |
Net capital distributions to non-controlling interest | | — | | | (3) | | | — | | | — | | | (3) | | | (2) | | | (5) | |
Balance at June 30, 2023 | | 137 | | | $ | 2,024 | | | $ | 2,636 | | | $ | (63) | | | $ | 4,597 | | | $ | 56 | | | $ | 4,653 | |
Net (loss) income | | — | | | — | | | (399) | | | — | | | (399) | | | 3 | | | (396) | |
Other comprehensive loss, net of taxes | | — | | | — | | | — | | | (32) | | | (32) | | | — | | | (32) | |
Issuances of stock | | 1 | | | 12 | | | — | | | — | | | 12 | | | — | | | 12 | |
Repurchases of stock and other | | — | | | (1) | | | — | | | — | | | (1) | | | — | | | (1) | |
Dividends of $0.36 per share | | — | | | — | | | (51) | | | — | | | (51) | | | — | | | (51) | |
Stock-based compensation | | — | | | 20 | | | — | | | — | | | 20 | | | — | | | 20 | |
Net capital distributions to non-controlling interest | | — | | | — | | | — | | | — | | | — | | | (2) | | | (2) | |
Balance at September 29, 2023 | | 138 | | | $ | 2,055 | | | $ | 2,186 | | | $ | (95) | | | $ | 4,146 | | | $ | 57 | | | $ | 4,203 | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
See accompanying notes to condensed consolidated financial statements.
4
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Shares of common stock | | Additional paid-in capital | | Retained earnings | | Accumulated other comprehensive income (loss) | | Leidos stockholders' equity | | Non-controlling interest | | Total stockholders' equity |
| | (unaudited; in millions, except per share data) |
Balance at December 31, 2021 | | 140 | | | $ | 2,423 | | | $ | 1,880 | | | $ | (12) | | | $ | 4,291 | | | $ | 53 | | | $ | 4,344 | |
Net income | | — | | | — | | | 175 | | | — | | | 175 | | | 2 | | | 177 | |
Other comprehensive income, net of taxes | | — | | | — | | | — | | | 32 | | | 32 | | | — | | | 32 | |
Issuances of stock | | 1 | | | 15 | | | — | | | — | | | 15 | | | — | | | 15 | |
Repurchases of stock and other | | (4) | | | (526) | | | — | | | — | | | (526) | | | — | | | (526) | |
Dividends of $0.36 per share | | — | | | — | | | (48) | | | — | | | (48) | | | — | | | (48) | |
Stock-based compensation | | — | | | 16 | | | — | | | — | | | 16 | | | — | | | 16 | |
Net capital distributions to non-controlling interest | | — | | | — | | | — | | | — | | | — | | | (2) | | | (2) | |
Balance at April 1, 2022 | | 137 | | | $ | 1,928 | | | $ | 2,007 | | | $ | 20 | | | $ | 3,955 | | | $ | 53 | | | $ | 4,008 | |
Net income | | — | | | — | | | 171 | | | — | | | 171 | | | 1 | | | 172 | |
Other comprehensive loss, net of taxes | | — | | | — | | | — | | | (99) | | | (99) | | | — | | | (99) | |
Issuances of stock | | — | | | 10 | | | — | | | — | | | 10 | | | — | | | 10 | |
Repurchases of stock and other | | — | | | (2) | | | — | | | — | | | (2) | | | — | | | (2) | |
Dividends of $0.36 per share | | — | | | — | | | (50) | | | — | | | (50) | | | — | | | (50) | |
Stock-based compensation | | — | | | 19 | | | — | | | — | | | 19 | | | — | | | 19 | |
Net capital distributions to non-controlling interest | | — | | | — | | | — | | | — | | | — | | | (1) | | | (1) | |
Balance at July 1, 2022 | | 137 | | | $ | 1,955 | | | $ | 2,128 | | | $ | (79) | | | $ | 4,004 | | | $ | 53 | | | $ | 4,057 | |
Net income | | — | | | — | | | 162 | | | — | | | 162 | | | 2 | | | 164 | |
Other comprehensive loss, net of taxes | | — | | | — | | | — | | | (56) | | | (56) | | | — | | | (56) | |
Issuances of stock | | — | | | 13 | | | — | | | — | | | 13 | | | — | | | 13 | |
Repurchases of stock and other | | — | | | (4) | | | — | | | — | | | (4) | | | — | | | (4) | |
Dividends of $0.36 per share | | — | | | — | | | (51) | | | — | | | (51) | | | — | | | (51) | |
Stock-based compensation | | — | | | 18 | | | — | | | — | | | 18 | | | — | | | 18 | |
Net capital distributions to non-controlling interest | | — | | | — | | | — | | | — | | | — | | | (2) | | | (2) | |
Balance at September 30, 2022 | | 137 | | | $ | 1,982 | | | $ | 2,239 | | | $ | (135) | | | $ | 4,086 | | | $ | 53 | | | $ | 4,139 | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
See accompanying notes to condensed consolidated financial statements.
5
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | | | | | | | | |
| | Nine Months Ended |
| | September 29, 2023 | | September 30, 2022 |
| | (unaudited; in millions) |
Cash flows from operations: | | | | |
Net (loss) income | | $ | (22) | | | $ | 513 | |
Adjustments to reconcile net (loss) income to net cash provided by operations: | | | | |
Depreciation and amortization | | 248 | | | 249 | |
Stock-based compensation | | 57 | | | 53 | |
Deferred income taxes | | (192) | | | (221) | |
Goodwill impairment charges | | 599 | | | — | |
Asset impairment charges | | 88 | | | 3 | |
Other | | 25 | | | 21 | |
Change in assets and liabilities, net of effects of acquisitions and dispositions: | | | | |
Receivables | | (109) | | | (139) | |
Other current assets and other long-term assets | | 141 | | | 132 | |
Accounts payable and accrued liabilities and other long-term liabilities | | 22 | | | (70) | |
Accrued payroll and employee benefits | | 105 | | | 217 | |
Income taxes receivable/payable | | (101) | | | 109 | |
Net cash provided by operating activities | | 861 | | | 867 | |
Cash flows from investing activities: | | | | |
Acquisition of a business, net of cash acquired | | (6) | | | (2) | |
Divestiture of a business | | — | | | 15 | |
Payments for property, equipment and software | | (129) | | | (76) | |
Net proceeds from sale of assets | | — | | | 6 | |
Other | | — | | | 2 | |
Net cash used in investing activities | | (135) | | | (55) | |
Cash flows from financing activities: | | | | |
Proceeds from debt issuance | | 1,743 | | | 380 | |
| | | | |
Repayments of borrowings | | (2,041) | | | (459) | |
Payments for debt issuance costs | | (7) | | | — | |
Dividend payments | | (150) | | | (149) | |
Repurchases of stock and other | | (44) | | | (532) | |
Proceeds from issuances of stock | | 37 | | | 35 | |
Net capital distributions to non-controlling interests | | (8) | | | (5) | |
Net cash used in financing activities | | (470) | | | (730) | |
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | | — | | | 14 | |
Net increase in cash, cash equivalents and restricted cash | | 256 | | | 96 | |
Cash, cash equivalents and restricted cash at beginning of period | | 683 | | | 875 | |
Cash, cash equivalents and restricted cash at end of period | | 939 | | | 971 | |
Less: restricted cash at end of period | | 189 | | | 164 | |
Cash and cash equivalents at end of period | | $ | 750 | | | $ | 807 | |
See accompanying notes to condensed consolidated financial statements.
6
LEIDOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | | | | | | | | |
| | Nine Months Ended |
| | September 29, 2023 | | September 30, 2022 |
| | (unaudited; in millions) |
Supplementary cash flow information: | | | | |
Cash paid for income taxes, net of refunds | | $ | 325 | | | $ | 166 | |
Cash paid for interest | | 160 | | | 136 | |
Non-cash investing activity: | | | | |
Property, plant and equipment additions | | $ | 2 | | | $ | 7 | |
Non-cash financing activity: | | | | |
Finance lease obligations | | $ | 65 | | | $ | 1 | |
See accompanying notes to condensed consolidated financial statements.
7
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Note 1–Basis of Presentation and Summary of Significant Accounting Policies
Nature of Operations and Basis of Presentation
Leidos Holdings, Inc. ("Leidos"), a Delaware corporation, is a holding company whose direct 100%-owned subsidiary and principal operating company is Leidos, Inc. Leidos is a FORTUNE 500® technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil and health markets, both domestically and internationally. Leidos' customers include the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs and many other U.S. civilian, state and local government agencies, foreign government agencies and commercial businesses. Unless indicated otherwise, references to "we," "us" and "our" refer collectively to Leidos Holdings, Inc. and its consolidated subsidiaries. We operate in three reportable segments: Defense Solutions, Civil and Health. Additionally, we separately present the unallocable costs associated with corporate functions as Corporate.
We have a controlling interest in Mission Support Alliance, LLC ("MSA"), a joint venture with Centerra Group, LLC. We also have a controlling interest in Hanford Mission Integration Solutions, LLC ("HMIS"), the legal entity for the follow-on contract to MSA's contract and a joint venture with Centerra Group, LLC and Parsons Government Services, Inc. The financial results for MSA and HMIS are consolidated into our unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements also include the balances of all voting interest entities in which Leidos has a controlling voting interest ("subsidiaries") and a variable interest entity ("VIE") in which Leidos is the primary beneficiary. The consolidated balances of the VIE are not material to the unaudited condensed consolidated financial statements for the periods presented. Intercompany accounts and transactions between consolidated companies have been eliminated in consolidation.
The accompanying unaudited condensed consolidated financial statements has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, right-of-use assets and lease liabilities, fair value and impairment of intangible assets and goodwill, income taxes, stock-based compensation expense and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates.
Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. We combined "Bad debt expense and recoveries" into "Selling, general and administrative expenses" on the condensed consolidated statements of operations. We have certain entities where the functional currency is not the U.S. dollar and have separately presented the effect of exchange rate changes on cash, cash equivalents and restricted cash held in foreign currencies as a separate line in the condensed consolidated statements of cash flows.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation thereof. The results reported in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the entire year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K filed on February 14, 2023.
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Accounting Standards Updates Issued and Adopted
ASU 2020-04, ASU 2021-01 and ASU 2022-06, Reference Rate Reform (ASC 848)
In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-04, which provides companies with optional expedients and exceptions to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. This update provides optional expedients for applying accounting guidance to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this update are effective for all entities as of March 2020 and can be adopted using a prospective approach no later than December 31, 2022.
In January 2021, the FASB issued ASU 2021-01 which amends the scope of ASU 2020-04. The amendments in this update are elective and provide optional relief for entities with hedge accounting and contract modifications affected by the transition from LIBOR through December 31, 2022. In December 2022, the FASB issued ASU 2022-06 which extends the deadline for application of ASU 2021-01 through December 31, 2024. Under this relief, entities may continue to account for contract modifications as a continuation of the existing contract and the continuation of the hedge accounting arrangement. In the first half of fiscal 2023, we adopted certain practical expedients available under ASC 848. Our term loans are based on a Secured Overnight Financing Rate (“SOFR”) rate (see "Note 6–Debt"). Additionally, we modified our interest rate swap agreements to reference SOFR (see "Note 5–Derivative Instruments") in conformity with the relief available under ASC 848. The standard did not have a material impact on our financial position, results of operations or earnings per share.
Changes in Estimates on Contracts
Changes in estimates related to contracts accounted for using the cost-to-cost method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes, with the exception of contracts acquired through a business combination, where the adjustment is made for the period commencing from the date of acquisition.
Changes in estimates on contracts were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | Nine Months Ended |
| | September 29, 2023 | | September 30, 2022 | | September 29, 2023 | | September 30, 2022 |
| | (in millions, except per share data) |
Favorable impact | | $ | 40 | | | $ | 36 | | | $ | 102 | | | $ | 116 | |
Unfavorable impact | | (24) | | | (29) | | | (62) | | | (75) | |
Net impact to (loss) income before income taxes | | $ | 16 | | | $ | 7 | | | $ | 40 | | | $ | 41 | |
| | | | | | | | |
Impact on diluted EPS attributable to Leidos common stockholders | | $ | 0.09 | | | $ | 0.03 | | | $ | 0.22 | | | $ | 0.22 | |
The impact on diluted earnings per share ("EPS") attributable to Leidos common stockholders is calculated using the statutory tax rate.
Revenue Recognized from Prior Obligations
Revenue recognized from performance obligations satisfied in previous periods was $13 million and $14 million for the three and nine months ended September 29, 2023, respectively, and $6 million and $38 million for the three and nine months ended September 30, 2022, respectively. The changes primarily related to revisions of variable consideration including award and incentive fees, and revisions to estimates at completion resulting from changes in contract scope, mitigation of contract risks or true-ups of contract estimates at the end of contract performance.
Cash and Cash Equivalents
Our cash equivalents are primarily comprised of investments in several large institutional money market accounts, with original maturity of three months or less. At September 29, 2023, and December 30, 2022, $64 million and $158 million, respectively, of outstanding payments were included within "Cash and cash equivalents" and "Accounts payable and accrued liabilities" correspondingly on the condensed consolidated balance sheets.
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Restricted Cash
We have restricted cash balances, primarily representing advances from customers that are restricted for use on certain expenditures related to that customer's contract. Restricted cash balances are included as "Other current assets" in the condensed consolidated balance sheets. Our restricted cash balances were $189 million and $167 million at September 29, 2023, and December 30, 2022, respectively.
Note 2–Revenues
Remaining Performance Obligations
Remaining performance obligations ("RPO") represent the expected value of exercised contracts, both funded and unfunded, less revenue recognized to date. RPO does not include unexercised option periods and future potential task orders expected to be awarded under indefinite delivery/indefinite quantity ("IDIQ") contracts, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.
As of September 29, 2023, we had $15.5 billion of RPO and expect to recognize approximately 63% and 79% over the next 12 months and 24 months, respectively, with the remainder to be recognized thereafter.
Disaggregation of Revenues
We disaggregate revenues by customer-type, contract-type and geographic location for each of our reportable segments.
Disaggregated revenues by customer-type were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 29, 2023 | | Nine Months Ended September 29, 2023 |
| | Defense Solutions | | Civil | | Health | | Total | | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
DoD and U.S. Intelligence Community | | $ | 1,677 | | | $ | 28 | | | $ | 242 | | | $ | 1,947 | | | $ | 4,798 | | | $ | 71 | | | $ | 755 | | | $ | 5,624 | |
Other U.S. government agencies(1) | | 261 | | | 695 | | | 512 | | | 1,468 | | | 772 | | | 2,054 | | | 1,413 | | | 4,239 | |
Commercial and non-U.S. customers | | 283 | | | 177 | | | 22 | | | 482 | | | 948 | | | 512 | | | 66 | | | 1,526 | |
Total | | $ | 2,221 | | | $ | 900 | | | $ | 776 | | | $ | 3,897 | | | $ | 6,518 | | | $ | 2,637 | | | $ | 2,234 | | | $ | 11,389 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, 2022 | | Nine Months Ended September 30, 2022 |
| | Defense Solutions | | Civil | | Health | | Total | | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
DoD and U.S. Intelligence Community | | $ | 1,559 | | | $ | 22 | | | $ | 255 | | | $ | 1,836 | | | $ | 4,620 | | | $ | 62 | | | $ | 732 | | | $ | 5,414 | |
Other U.S. government agencies(1) | | 236 | | | 676 | | | 372 | | | 1,284 | | | 686 | | | 1,949 | | | 1,177 | | | 3,812 | |
Commercial and non-U.S. customers | | 280 | | | 151 | | | 28 | | | 459 | | | 869 | | | 446 | | | 83 | | | 1,398 | |
Total | | $ | 2,075 | | | $ | 849 | | | $ | 655 | | | $ | 3,579 | | | $ | 6,175 | | | $ | 2,457 | | | $ | 1,992 | | | $ | 10,624 | |
(1) Includes federal government agencies other than the DoD and U.S. Intelligence Community, as well as state and local government agencies.
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Disaggregated revenues by contract-type were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 29, 2023 | | Nine Months Ended September 29, 2023 |
| | Defense Solutions | | Civil | | Health | | Total | | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
Cost-reimbursement and fixed-price-incentive-fee | | $ | 1,247 | | | $ | 472 | | | $ | 131 | | | $ | 1,850 | | | $ | 3,578 | | | $ | 1,401 | | | $ | 542 | | | $ | 5,521 | |
Firm-fixed-price | | 718 | | | 286 | | | 543 | | | 1,547 | | | 2,128 | | | 813 | | | 1,396 | | | 4,337 | |
Time-and-materials and fixed-price-level-of-effort | | 256 | | | 142 | | | 102 | | | 500 | | | 812 | | | 423 | | | 296 | | | 1,531 | |
Total | | $ | 2,221 | | | $ | 900 | | | $ | 776 | | | $ | 3,897 | | | $ | 6,518 | | | $ | 2,637 | | | $ | 2,234 | | | $ | 11,389 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, 2022 | | Nine Months Ended September 30, 2022 |
| | Defense Solutions | | Civil | | Health | | Total | | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
Cost-reimbursement and fixed-price-incentive-fee | | $ | 1,166 | | | $ | 442 | | | $ | 200 | | | $ | 1,808 | | | $ | 3,493 | | | $ | 1,293 | | | $ | 534 | | | $ | 5,320 | |
Firm-fixed-price | | 668 | | | 279 | | | 389 | | | 1,336 | | | 1,950 | | | 792 | | | 1,260 | | | 4,002 | |
Time-and-materials and fixed-price-level-of-effort | | 241 | | | 128 | | | 66 | | | 435 | | | 732 | | | 372 | | | 198 | | | 1,302 | |
Total | | $ | 2,075 | | | $ | 849 | | | $ | 655 | | | $ | 3,579 | | | $ | 6,175 | | | $ | 2,457 | | | $ | 1,992 | | | $ | 10,624 | |
Disaggregated revenues by geographic location were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 29, 2023 | | Nine Months Ended September 29, 2023 |
| | Defense Solutions | | Civil | | Health | | Total | | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
United States | | $ | 1,936 | | | $ | 845 | | | $ | 776 | | | $ | 3,557 | | | $ | 5,659 | | | $ | 2,504 | | | $ | 2,234 | | | $ | 10,397 | |
International | | 285 | | | 55 | | | — | | | 340 | | | 859 | | | 133 | | | — | | | 992 | |
Total | | $ | 2,221 | | | $ | 900 | | | $ | 776 | | | $ | 3,897 | | | $ | 6,518 | | | $ | 2,637 | | | $ | 2,234 | | | $ | 11,389 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended September 30, 2022 | | Nine Months Ended September 30, 2022 |
| | Defense Solutions | | Civil | | Health | | Total | | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
United States | | $ | 1,830 | | | $ | 810 | | | $ | 655 | | | $ | 3,295 | | | $ | 5,429 | | | $ | 2,340 | | | $ | 1,992 | | | $ | 9,761 | |
International | | 245 | | | 39 | | | — | | | 284 | | | 746 | | | 117 | | | — | | | 863 | |
Total | | $ | 2,075 | | | $ | 849 | | | $ | 655 | | | $ | 3,579 | | | $ | 6,175 | | | $ | 2,457 | | | $ | 1,992 | | | $ | 10,624 | |
Revenues by customer-type, contract-type and geographic location exclude lease income of $24 million and $69 million for the three and nine months ended September 29, 2023, respectively, and $29 million and $75 million for the three and nine months ended September 30, 2022, respectively.
Contract Assets and Liabilities
Performance obligations are satisfied either over time as work progresses or at a point in time. Firm-fixed-price contracts are typically billed to the customer using milestone payments while cost-reimbursable and time and materials contracts are typically billed to the customer on a monthly or bi-weekly basis as indicated by the negotiated billing terms and conditions of the contract. As a result, the timing of revenue recognition, customer billings and cash collections for each contract results in a net contract asset or liability at the end of each reporting period.
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Contract assets consist of unbilled receivables, which is the amount of revenue recognized that exceeds the amount billed to the customer. Unbilled receivables exclude amounts billable where the right to consideration is solely subject to the passage of time. Contract liabilities consist of deferred revenue, which represents cash advances received prior to performance for programs and billings in excess of revenue recognized.
The components of contract assets and contract liabilities consisted of the following: | | | | | | | | | | | | | | | | | | | | |
| | Balance sheet line item | | September 29, 2023 | | December 30, 2022 |
| | | | (in millions) |
Contract assets - current: | | | | | | |
Unbilled receivables | | Receivables, net | | $ | 1,047 | | | $ | 1,010 | |
| | | | | | |
Contract liabilities - current: | | | | | | |
Deferred revenue(1) | | Accounts payable and accrued liabilities | | $ | 449 | | | $ | 380 | |
| | | | | | |
Contract liabilities - non-current: | | | | | | |
Deferred revenue(1) | | Other long-term liabilities | | $ | 23 | | | $ | 29 | |
(1) Certain contracts record revenue net of cost of revenues, and therefore, the respective deferred revenue balance will not fully convert to revenue.
Revenue recognized for the three and nine months ended September 29, 2023, of $28 million and $215 million, respectively, was included as a contract liability at December 30, 2022. Revenue recognized for the three and nine months ended September 30, 2022, of $17 million and $257 million, respectively, was included as a contract liability at December 31, 2021.
Note 3–Acquisitions, Divestitures, Goodwill and Intangible Assets
Business Acquisition
On October 30, 2022 (the "Agreement Date"), we completed the acquisition of Cobham Special Mission for purchase consideration of $298 million Australian dollars, net of $10 million of Australian dollars acquired, or $192 million United States dollars, net of $6 million of cash acquired. Cobham Special Mission provides airborne border surveillance and search and rescue services to the Australian Federal Government.
As of September 29, 2023, we completed the determination of fair values of the assets acquired and liabilities assumed.The final goodwill recognized of $22 million represents intellectual capital and the acquired assembled workforce, neither of which qualify for recognition as a separate intangible asset. None of the goodwill recognized is tax deductible.
In connection with this acquisition, we acquired property, plant and equipment with a fair value of $148 million at the Agreement Date. The following table summarizes the fair value of intangible assets acquired at the Agreement Date and the related weighted average amortization period:
| | | | | | | | | | | | | | |
| | Weighted average amortization period | | Fair value |
| | (in years) | | (in millions) |
Programs | | 11 | | $ | 19 | |
Technology | | 10 | | 5 | |
Total | | 11 | | $ | 24 | |
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
For the three and nine months ended September 29, 2023, $28 million and $86 million of revenues related to the Cobham Special Mission acquisition were recognized within the Defense Solutions reportable segment.
Goodwill
The following table presents changes in the carrying amount of goodwill by reportable segment: | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Defense Solutions | | Civil | | Health | | Total |
| | (in millions) |
Goodwill at December 31, 2021(1) | | $ | 3,681 | | | $ | 2,097 | | | $ | 966 | | | $ | 6,744 | |
Acquisition of businesses | | 26 | | | — | | | — | | | 26 | |
Divestiture of a business | | (6) | | | — | | | — | | | (6) | |
Foreign currency translation adjustments | | (37) | | | (31) | | | — | | | (68) | |
Goodwill at December 30, 2022(1) | | $ | 3,664 | | | $ | 2,066 | | | $ | 966 | | | $ | 6,696 | |
Goodwill impairment | | — | | | (599) | | | — | | | (599) | |
Acquisition of a business(2) | | (4) | | | — | | | — | | | (4) | |
Foreign currency translation adjustments | | (18) | | | 4 | | | — | | | (14) | |
Goodwill at September 29, 2023(3) | | $ | 3,642 | | | $ | 1,471 | | | $ | 966 | | | $ | 6,079 | |
(1) Carrying amount includes accumulated impairment losses of $369 million and $117 million within the Health and Civil segments, respectively.
(2) Adjustment to goodwill resulting from a measurement period purchase accounting adjustment.
(3) Carrying amount includes accumulated impairment losses of $369 million and $716 million within the Health and Civil segments, respectively.
We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners or litigation.
Operations of the Security Enterprise Solutions (“SES”) reporting unit rely heavily on the sales and servicing of security and detection products, which continue to be negatively impacted due to delays in airline travel infrastructure projects as customer budgetary restraints recover from reduced travel activity post-pandemic. During the third quarter of fiscal 2023, the SES reporting unit refined its portfolio and made strategic business decisions to exit certain product offerings, as well as cease operations in certain countries in order to align the operations of the reporting unit with its strategic business plan. These decisions, along with the delays in airline travel infrastructure projects and higher than anticipated servicing costs, contributed to a significant reduction in the reporting unit’s forecasted revenue and cash flows.
As a result, we conducted an interim quantitative goodwill impairment analysis and our estimates led us to determine that the carrying value of the SES reporting unit exceeded its estimated fair value (see “Note 4–Fair Value Measurements”). Accordingly, we recognized a non-cash goodwill impairment charge of $599 million for the three and nine months ended September 29, 2023, leaving $303 million of goodwill at the SES reporting unit. The impairment was recorded within the Civil reportable segment in the condensed consolidated statements of operations. In the event that there are significant unfavorable changes to the forecasted cash flows, forecasted revenue, terminal growth rates or the cost of capital used in the fair value estimates, we may be required to record an additional impairment of goodwill at a future date.
.
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Intangible Assets
Intangible assets, net consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | September 29, 2023 | | December 30, 2022 |
| | Gross carrying value | | Accumulated amortization | | Net carrying value | | Gross carrying value | | Accumulated amortization | | Net carrying value |
| | (in millions) |
Finite-lived intangible assets: | | | | | | | | | | | | |
Programs | | $ | 1,686 | | | $ | (1,132) | | | $ | 554 | | | $ | 1,721 | | | $ | (1,016) | | | $ | 705 | |
Software and technology | | 203 | | | (138) | | | 65 | | | 225 | | | (136) | | | 89 | |
Customer relationships | | 52 | | | (21) | | | 31 | | | 87 | | | (25) | | | 62 | |
Trade names | | 1 | | | (1) | | | — | | | 1 | | | (1) | | | — | |
Total finite-lived intangible assets | | 1,942 | | | (1,292) | | | 650 | | | 2,034 | | | (1,178) | | | 856 | |
Indefinite-lived intangible assets: | | | | | | | | | | | | |
In-process research and development ("IPR&D")(1) | | 59 | | | — | | | 59 | | | 92 | | | — | | | 92 | |
Trade names | | 4 | | | — | | | 4 | | | 4 | | | — | | | 4 | |
Total indefinite-lived intangible assets | | 63 | | | — | | | 63 | | | 96 | | | — | | | 96 | |
Total intangible assets | | $ | 2,005 | | | $ | (1,292) | | | $ | 713 | | | $ | 2,130 | | | $ | (1,178) | | | $ | 952 | |
(1) IPR&D assets are indefinite-lived at the acquisition date until placed into service, at which time such assets will be reclassified to a finite-lived amortizable intangible asset.
Our strategic decisions regarding SES’ product offerings and operating regions (see the goodwill discussion on page 13) caused certain technology and IPR&D intangible assets to be abandoned and the carrying values of certain program intangible assets to become unrecoverable. As a result, for the three and nine months ended September 29, 2023, we recognized intangible asset impairment charges of $79 million. The impairment was recorded to “Asset impairment charges” in the condensed consolidated statements of operations within the Civil reportable segment. In the event that we are required to make an additional impairment of goodwill at a future date for any of the reasons identified in our discussion of goodwill or if other events occur that negatively impact these intangible assets, we may also be required to record an additional impairment of intangible assets at that time.
Amortization expense was $50 million and $153 million for the three and nine months ended September 29, 2023, respectively and $57 million and $173 million for the three and nine months ended September 30, 2022, respectively.
Program intangible assets are amortized over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows. Backlog and finite-lived trade name intangible assets are amortized on a straight-line basis over their estimated useful lives. Customer relationships and software and technology intangible assets are amortized either on a straight-line basis over their estimated useful lives or over their respective estimated useful lives in proportion to the pattern of economic benefit based on expected future discounted cash flows, as deemed appropriate.
LEIDOS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
The estimated annual amortization expense as of September 29, 2023, was as follows: